Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christos Chatzikyrkou

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
Journal of Hypertension|December 11, 2012
Targeting albuminuria in arterial hypertension and diabetes: how is it best achieved and what is its clinical relevance?Christos Chatzikyrkou, Jan Menne
Nature Reviews. Nephrology|September 11, 2013
Diabetes: Legacy effects of RAS blockade in diabetes mellitusChristos Chatzikyrkou, Jan Menne
Expert Review of Cardiovascular Therapy|October 27, 2012
Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in type 2 diabetesChristos Chatzikyrkou, Jan Menne
Nature Reviews. Endocrinology|April 25, 2012
Diabetes: hyperfiltration-a risk factor for nephropathy in T1DM?Christos Chatzikyrkou, Hermann Haller
Journal of Hypertension|July 17, 2010
Microalbuminuria as a risk factor: the influence of renin-angiotensin system blockadeJan Menne, Christos Chatzikyrkou, Hermann Haller
Medizinische Klinik (Munich, Germany : 1983)|August 25, 2009
[Hypertension 2007-2008]Christos Chatzikyrkou, Jan Menne, Hermann Haller
Expert Opinion on Pharmacotherapy|June 17, 2009
The role of fixed-dose combinations in the management of hypertension: focus on lercanidipine-enalaprilChristos Chatzikyrkou, Hermann Haller, Jan Menne
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|June 4, 2009
How to achieve renal protection in the light of ONTARGET?Christos Chatzikyrkou, Jan Menne, Hermann Haller
Current Hypertension Reports|May 7, 2021
Update on Treatment of Hypertension After Renal TransplantationChristos Chatzikyrkou, Roland E Schmieder, Mario Schiffer
Lancet (London, England)|December 3, 2019
Clinical outcomes after ABO-incompatible renal transplantation - Authors' replyFlorian Gunnar Scurt, Peter René Mertens, Christos Chatzikyrkou
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Journal of Hypertension|December 11, 2012
Targeting albuminuria in arterial hypertension and diabetes: how is it best achieved and what is its clinical relevance?Christos Chatzikyrkou, Jan Menne
Nature Reviews. Nephrology|September 11, 2013
Diabetes: Legacy effects of RAS blockade in diabetes mellitusChristos Chatzikyrkou, Jan Menne
Expert Review of Cardiovascular Therapy|October 27, 2012
Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in type 2 diabetesChristos Chatzikyrkou, Jan Menne
Nature Reviews. Endocrinology|April 25, 2012
Diabetes: hyperfiltration-a risk factor for nephropathy in T1DM?Christos Chatzikyrkou, Hermann Haller
Journal of Hypertension|July 17, 2010
Microalbuminuria as a risk factor: the influence of renin-angiotensin system blockadeJan Menne, Christos Chatzikyrkou, Hermann Haller
Medizinische Klinik (Munich, Germany : 1983)|August 25, 2009
[Hypertension 2007-2008]Christos Chatzikyrkou, Jan Menne, Hermann Haller
Expert Opinion on Pharmacotherapy|June 17, 2009
The role of fixed-dose combinations in the management of hypertension: focus on lercanidipine-enalaprilChristos Chatzikyrkou, Hermann Haller, Jan Menne
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|June 4, 2009
How to achieve renal protection in the light of ONTARGET?Christos Chatzikyrkou, Jan Menne, Hermann Haller
Current Hypertension Reports|May 7, 2021
Update on Treatment of Hypertension After Renal TransplantationChristos Chatzikyrkou, Roland E Schmieder, Mario Schiffer
Lancet (London, England)|December 3, 2019
Clinical outcomes after ABO-incompatible renal transplantation - Authors' replyFlorian Gunnar Scurt, Peter René Mertens, Christos Chatzikyrkou
Pageof 6